Adoptive transfer of T cells engineered to express a hepatitis B virus–specific (HBV-specific)
T cell receptor (TCR) may supplement HBV-specific immune responses in chronic HBV …

BACKGROUND & AIMS: Virus-specific T cells capable of controlling HBV and eliminating
hepatocellular carcinoma (HCC) expressing HBV antigens are deleted or dysfunctional in …

Hepatocellular carcinoma (HCC) cells often have hepatitis B virus (HBV)-DNA integration
and can be targeted by HBV-specific T cells. The use of viral vectors to introduce exogenous …

T cell therapy is a promising means to treat chronic hepatitis B virus (HBV) infection and
HBV-associated hepatocellular carcinoma. T cells engineered to express an HBV-specific T …

Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a
promising option for cancer treatment and could include hepatocellularcarcinoma (HCC) …

Background & Aims Antiviral agents suppress hepatitis B virus (HBV) replication but do not
clear the infection. A strong effector T-cell response is required to eradicate HBV, but this …

T-cell therapy of chronic hepatitis B is a novel approach to restore antiviral T-cell immunity
and cure the infection. We aimed at identifying T-cell receptors (TCR) with high functional …

Chronic hepatitis B virus (HBV) infection remains a major global concern due to its high
prevalence and the increased probability of progressing toward cirrhosis and hepatocellular …

Most people develop acute hepatitis B virus (HBV)-related hepatitis that is controlled by both
humoral and cellular immune responses following acute infection. However, a number of …

Background & Aims: The final goal in hepatitis B therapy is eradication of the hepatitis B
virus (HBV) replication template, the so-called covalently closed circular DNA (cccDNA) …